UNLOCK THE POTENTIAL OF GPEX® LIGHTNING: Accelerate Your HEK Cell Line Development
Abstract: Catalent has expanded its high-performance GPEx® Lightning platform to include Human Embryonic Kidney (HEK) cell line development, creating a new milestone for complex biologics. By merging advanced cell line engineering with site-specific integration technology, this breakthrough platform provides a faster, more flexible pathway for producing next-generation therapeutics such as viral vectors and multispecifics. The system circumvents traditional manufacturing hurdles like protein truncation and aggregation while ensuring proper human glycosylation patterns. With proven scalability from development to large-scale GMP bioreactors, HEK GPEx® Lightning offers developers a robust solution to accelerate their most challenging molecules from gene to market.